Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | CTRC | Q99895 | 1/20 | 0.50 |
| ▸ | RGS4 | P49798 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.48 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471071 | 0.93 | GAA (0.48) | MGLLELANEF2CTSGCMA1 | |
| SCHEMBL1471856 | 0.92 | LMNA (0.59) | MGLLELANEF2CTSGCMA1 | |
| SCHEMBL1471831 | 0.92 | LMNA (0.59) | MGLLELANEF2CTSGCMA1 | |
| SCHEMBL1471189 | 0.91 | ALDH1A1 (0.57) | MGLLELANEF2CTSGCMA1 | |
| SCHEMBL1471536 | 0.91 | RGS4 (0.57) | MGLLELANEF2CTSGCMA1 | |
| SCHEMBL1471797 | 0.89 | MGLL (0.50) | MGLLRGS4MAPTNPSR1TDP1 | |
| SCHEMBL1471737 | 0.89 | MGLL (0.50) | MGLLRGS4MAPTNPSR1TDP1 | |
| SCHEMBL1471713 | 0.85 | LMNA (0.49) | RGS4LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL1471652 | 0.84 | HSP90AA1 (0.54) | MGLLRGS4LMNAMAPTNPSR1 | |
| SCHEMBL6337999 | 0.83 | FAAH (0.53) | MGLLRGS4LMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915304-B2 | Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT | CONGENIA S.R.L. (IT) | 2011-03-29 | — | — | US | disclosed |
| EP-2091531-B1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S R L (IT) | 2010-11-24 | — | — | EP | disclosed |
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| EP-2091531-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | Congenia S.r.l. (IT) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008067863-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CYC1, MTPN, TXN2 | MGLL 857/4885ELANE 2570/4885F2 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.